The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genetics Breakthrough in Tilapia

11 Jul 2019 07:00

RNS Number : 1528F
Benchmark Holdings PLC
11 July 2019
 

 

Benchmark Holdings plc

 

("Benchmark" or the "Company")

Genetics breakthrough to increase resistance to Streptococcus iniae in tilapia

Addresses one of the biggest challenges in the world's second most farmed species

 

Benchmark, the aquaculture health, nutrition and genetics business, is pleased to announce a significant discovery to increase genetic resistance to Streptococcus iniae infections in tiliapia, one of the biggest challenges in the aquaculture industry.

 

Benchmark's team of geneticists have identified a significant quantitative trait locus (QTL), a small section of DNA, which is linked to increased levels of resistance to Streptococcus iniae. The Company has made a patent application in respect of this discovery.

 

The identified QTL will be used for commercial production of tilapia fry marking the first time that a significant QTL for disease resistance is used in commercial breeding of tilapia.

 

Tilapia is the world's second most farmed fish with 6.3 million tonnes of production in 2018 (estimated commercial value of £6.6 bn) and is growing at c. 5% CAGR (2017 - 2022) according to the United Nations Food and Agriculture Organisation.

 

Following this discovery, Benchmark's tilapia broodstock are selected both for improved resistance to Streptococcus agalactiae using genomic selection, and to Streptococcus iniae using the identified QTL in marker-assisted selection.

 

Malcolm Pye, CEO Benchmark commented:

 

"This is a major step forward for the tilapia industry. It is the result of Benchmark's many years of investment and commitment to bringing state-of-the-art breeding technology to this important farmed species.

 

"We believe that this breakthrough will allow the industry to expand production of this cost effective, high-quality, protein source to meet global demand for protein. We have seen first hand how devastating Streptococcus is to the industry and with the introduction of this new technology we can drive improvements in sustainability and profitability for our customers."

 

 

- ENDS -

 

Enquiries

 

Benchmark Holdings plc

Tel: 020 3915 1236

Malcolm Pye, CEO

 

Mark Plampin, CFO

 

Ivonne Cantu, Investor Relations

 

 

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Freddie Naylor-Leyland

 

 

 

MHP Communications

Tel: 020 3128 8226

Katie Hunt / Reg Hoare / Alistair de Kare-Silver benchmark@mphc.com

 

 

 

- ENDS -

 

About Benchmark Benchmark's mission is to enable food producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (artemia), sea lice treatments, training and data management tools. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRARMMFTMBIBBBL
Date   Source Headline
21st Jun 20214:41 pmRNSSecond Price Monitoring Extn
21st Jun 20214:36 pmRNSPrice Monitoring Extension
2nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
2nd Jun 20214:35 pmRNSPrice Monitoring Extension
28th May 20217:00 amRNSTotal Voting Rights
25th May 20217:00 amRNSDirector Dealings
18th May 20217:00 amRNSSecond Quarter and Interim results
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSNotice of Q2 and Interim Results
16th Apr 202111:00 amRNSBMK08+CleanTreat Update
31st Mar 20213:41 pmRNSDirector Dealings
31st Mar 20217:00 amRNSTotal Voting Rights
30th Mar 20217:00 amRNSListing of existing senior secured NOK bond
26th Mar 20218:24 amRNSBMK08+CleanTreat Update
19th Mar 20217:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
26th Feb 202110:52 amRNSTotal Voting Rights
22nd Feb 20217:00 amRNSQ1 Results
9th Feb 202112:43 pmRNSResult of AGM
9th Feb 20217:00 amRNSNotice of Q1 Results
29th Jan 20217:00 amRNSTotal Voting Rights
13th Jan 20217:00 amRNSIssue of Equity
8th Jan 20211:13 pmRNSReplacement: DIRECTOR SHARE OPTIONS
8th Jan 20219:57 amRNSDIRECTOR SHARE OPTIONS
6th Jan 20213:45 pmRNSDirector Dealings
31st Dec 20207:00 amRNSTotal Voting Rights
11th Dec 20205:32 pmRNSPosting of Annual Report and Notice of AGM
2nd Dec 20202:09 pmRNSDirector Dealings
1st Dec 20204:02 pmRNSAnnual Financial Report
1st Dec 202011:30 amRNSDirector Dealings
1st Dec 202010:30 amRNSDirector Dealings
1st Dec 202010:21 amRNSPCA Dealing
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSQ4 Results
27th Nov 20207:00 amRNSFull Year Results
18th Nov 20207:00 amRNSDirectorate Change
4th Nov 20207:00 amRNSInvestor Presentation for Retail Investors
30th Oct 20207:00 amRNSTotal Voting Rights
27th Oct 20207:00 amRNSNotice of Results
13th Oct 20202:29 pmRNSHolding(s) in Company
12th Oct 20202:50 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSTotal Voting Rights
29th Sep 20207:00 amRNSHolding(s) in Company
21st Sep 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.